Abstract
Abstract Objective The aim of this study was to evaluate the safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma (mRCC) and pleural effusion. Methods A total of 10 patients with mRCC (8 clear-cell RCCs, 1 papillary RCC, 1 chromophobe RCC) with pleural effusion from January 2014 to October 2015 were recruited. Four patients received sorafenib (400 mg, twice daily), while six received sunitinib (50 mg, once daily; 2 weeks on and 1 week off). All patients received multi-kinase inhibitor plus pleural cavity perfusion of endostar (15 mg on days 1-4 for 1 or 2 weeks). Results The response rate of pleural effusion was 70%. Adverse reactions were limited and mild. Conclusion The regimen of multi-kinase inhibitor plus pleural cavity perfusion of endostar was both effective and safe for the treatment of patients with mRCC with pleural effusion, and may control local symptoms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
